major depressive disorder

Relmada Therapeutics Inc's (NASDAQ: RLMD) RELIANCE III study (REL-1017-303) of REL-1017 in the monotherapy setting for Major Depressive Disorder (MDD) did not achieve its primary endpoint. The product candidate failed to achieve a statistically significant improvement in depression...

Cybin Inc. (NEO: CYBN) (NYSE AMERICAN: CYBN), a biopharmaceutical company focused on psychedelics for mental health, announced Tuesday that the first two participants have been dosed in its Phase 1/2a trial evaluating CYB003 for the treatment of the major depressive disorder (MDD). CYB003 is...

Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have announced 12-month data for the cohort of patients (n=199) who received zuranolone 50 mg once for 14-days as their initial dose in the ongoing Phase 3 open-label SHORELINE Study. Related: Sage...

AbbVie Inc (NYSE: ABBV) has announced topline results from two Phase 3 trials, Study 3111-301-001 and Study 3111-302-001, of cariprazine (Vraylar) as an adjunctive treatment for major depressive disorder (MDD).  In Study 3111-301-001, cariprazine showed a statistically significant...

B. Riley analyst calls Seelos Therapeutics Inc (NASDAQ: SEEL) his top "Battered Bastions" pick with the stock down 60% from intra-year highs.  Related: Why This Seelos Therapeutics Analyst Is Turning Bullish On Potential Trial Results. According to the analyst Mayank...

Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have announced data from WATERFALL Phase 3 study evaluating zuranolone (SAGE-217/BIIB125) in patients with Major Depressive Disorder (MDD). The 543-subject trial met its primary endpoint with...

The FDA has granted 501(k) clearance for BrainsWay Ltd's (NASDAQ: BWAY) Theta Burst three-minute protocol utilizing its Deep Transcranial Magnetic Stimulation (Deep TMS) system for major depressive disorder (MDD). "Many patients and providers can benefit from...

Under Priority review status, the FDA has accepted Axsome Therapeutics Inc's (NASDAQ: AXSM) marketing application for AXS-05 for major depressive disorder (MDD). The target action date is set at August 22. AXS-05 (dextromethorphan-bupropion) is an oral, investigational NMDA...

Shares of thinly-traded SAGE Therapeutics Inc NASDAQ: SAGE) are melting down after the company flunked in a late-stage trial of its lead CNS disorder drug candidate SAGE-217 in major depressive disorder, or MDD. What Happened To SAGE-217? Sage said its pivotal Phase 3 MOUNTAIN study evaluating...

SAGE Therapeutics Inc (NASDAQ: SAGE) released Thursday positive top-line data from its Phase 2 study of SAGE-217 in major depressive disorder (MDD). The news immediately propelled Sage's stock, rocketing it past previous highs to $169.58. Cowen thinks there’s still upside. The Rating...